No Data
Investors More Bullish on Shanghai Runda Medical Technology (SHSE:603108) This Week as Stock Hikes 16%, Despite Earnings Trending Downwards Over Past Five Years
Runda Healthcare: 2024 performance pre-reduction forecast
2024 Earnings Preliminary Reduction Forecast
Shanghai Runda Medical Technology (603108.SH): It is expected that the net income for 2024 will decrease by 81.16% to 84.3% compared to the previous year.
Gelonghui, on January 20, announced that Shanghai Runda Medical Technology (603108.SH) revealed that, according to preliminary calculations by the company's financial department, it is expected to achieve a net income attributable to the parent company's owners of 42.91 million yuan to 51.49 million yuan for 2024. Compared to the same period last year, this represents a decrease of 221.81 million yuan to 230.39 million yuan, a year-on-year decrease of 81.16% to 84.30%. It is expected that the net income attributable to the parent company's owners, excluding non-recurring gains and losses, will be 21.97 million yuan to 26.36 million yuan for 2024, a decrease of 123.04 million yuan to 127.43 million yuan compared to the same period last year.
Shanghai Runda Medical Technology Co., Ltd. (SHSE:603108) Looks Inexpensive After Falling 27% But Perhaps Not Attractive Enough
Shanghai Runda Medical Technology (603108.SH) plans to participate in the establishment of Fuzhou New Investment Zhikai Ruikang Venture Capital Fund, mainly investing in the medical and health sector.
Shanghai Runda Medical Technology (603108.SH) released an announcement, stating that the company plans to collaborate with Shanghai Zhikai Asset Management Co., Ltd. (abbreviated as "...")
How Good Is Shanghai Runda Medical Technology Co., Ltd. (SHSE:603108), When It Comes To ROE?
